Stocks and Investing
Stocks and Investing
Fri, August 7, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Chris Howerton Downgraded (TXMD) to Sell and Decreased Target to $60 on, Aug 7th, 2020
Chris Howerton of Jefferies, Downgraded "TherapeuticsMD, Inc." (TXMD) to Sell and Decreased Target from $63 to $60 on, Aug 7th, 2020.
Chris has made no other calls on TXMD in the last 4 months.
There are 3 other peers that have a rating on TXMD. Out of the 3 peers that are also analyzing TXMD, 1 agrees with Chris's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chris Schott of "JP Morgan" Downgraded from Buy to Hold on, Tuesday, May 19th, 2020
These are the ratings of the 2 analyists that currently disagree with Chris
- Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy with Decreased Target to $250 on, Thursday, May 7th, 2020
- Annabel Samimy of "Stifel" Maintained at Strong Buy with Increased Target to $750 on, Thursday, April 16th, 2020